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Abstract
Background: Advances in the understanding and management of pulmonary arterial hypertension have enabled
earlier diagnosis and improved prognosis. However, despite best available therapy, symptoms of exertional
dyspnoea and fatigue are commonly reported and result in a reduced capacity to perform daily activities and
impaired quality of life. Exercise training has demonstrated efficacy in individuals with other respiratory and
cardiovascular diseases. Historically, however, exercise training has not been utilised as a form of therapy in
pulmonary arterial hypertension due to the perceived risk of sudden cardiac death and the theoretical possibility
that exercise would lead to worsening pulmonary vascular haemodynamics and deterioration in right heart
function. Now, with the advances in pharmaceutical management, determining the safety and benefits of exercise
training in this population has become more relevant. Only three studies of supervised exercise training in
pulmonary arterial hypertension have been published. These studies demonstrated improvements in exercise
capacity and quality of life, in the absence of adverse events or clinical deterioration. However, these studies have
not utilised an outpatient-based, whole body exercise training program, the most common format for exercise
programs within Australia. It is uncertain whether this form of training is beneficial and capable of producing
sustained benefits in exercise capacity and quality of life in this population.
Design/Methods: This randomised controlled trial will determine whether a 12 week, outpatient-based, supervised,
whole body exercise training program, followed by a home-based exercise program, is safe and improves exercise
capacity and quality of life in individuals with pulmonary arterial hypertension. This study aims to recruit 34
subjects who will be randomly allocated to the exercise group (supervised exercise training 3 times a week for 12
weeks, followed by 3 sessions per week of home exercise for 12 weeks) or the control group (usual medical care).
Subjects will be assessed at baseline, 12 weeks and 24 weeks.
Discussion: This study will determine whether outpatient-based, whole body exercise training is beneficial and
safe in individuals with pulmonary arterial hypertension. Additionally, this study will contribute to clinical practice
guidelines for this patient population.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN12609000502235
* Correspondence: louise.ganderton@health.wa.gov.au
1School of Physiotherapy and Curtin Health Innovation Research Institute,
Curtin University, Perth, Australia
Full list of author information is available at the end of the article
Ganderton et al. BMC Pulmonary Medicine 2011, 11:25
http://www.biomedcentral.com/1471-2466/11/25
© 2011 Ganderton et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Background
Pulmonary arterial hypertension (PAH) is characterised
by pathological changes in the pulmonary vasculature
that cause an increase in pulmonary vascular resistance
(PVR) thereby restricting blood flow through the
pulmonary circulation [1,2]. To maintain blood flow,
pulmonary artery pressure (PAP) increases [2]. Disease
progression leads to right ventricular dysfunction and
right heart failure [3,4]. The physiologic response of the
pulmonary vasculature to exercise is markedly different
from normal in individuals with PAH [1,5]. The pul-
monary arteries and arterioles have an impaired capacity
to vasodilate and distend, and the increase in cardiac
output required to accommodate the metabolic require-
ments of exercise is limited [1]. As a result, oxygen
delivery to the peripheral muscles is impaired [6], con-
tributing to the symptoms of muscle fatigue and dys-
pnoea [1,5]. Whilst the impairment in cardiac output to
meet peripheral oxygen demands during exercise largely
contributes to the reduction in exercise capacity [7],
skeletal muscle dysfunction may also be implicated in
the exercise limitation experienced by individuals with
PAH [7-10]. Several studies have demonstrated signifi-
cant morphological and functional changes in skeletal
musculature [8-13], which may be related to the
decrease in systemic oxygen transport [7]. Changes such
as muscle atrophy, decreased oxidative enzymes and
increased proportion of type II muscle fibres lead to
the early onset of lactic acidosis and a reduced aerobic
capacity [7,9,10]
Despite advances in pharmaceutical therapies, which
have resulted in improvements in exercise capacity, hae-
modynamics and outcome in patients with PAH [14],
exertional dyspnoea and fatigue continue to result in
difficulty performing activities of daily living, lead to the
avoidance of physical activity and adversely impact on
health-related quality of life (HRQoL) [15]. This inactiv-
ity and the resultant physical deconditioning are likely
to further exacerbate the functional limitations
associated with PAH [8].
Whilst there is a paucity of studies in the PAH popu-
lation, the benefits of exercise training in individuals
with other cardiopulmonary conditions are well estab-
lished. Specifically, improvements in symptoms, exercise
capacity, peripheral muscle function and HRQoL are
well documented following exercise training in chronic
left-sided heart failure [16-19] and in chronic obstruc-
tive pulmonary disease (COPD) [20-23], populations
that both report exertional symptoms similar to PAH.
These benefits have been achieved following supervised
exercise training, 2 to 3 times per week for a period of 6
to 12 weeks, which comprised endurance exercise at a
target intensity of between 40 and 80% of peak exercise
capacity (peak oxygen uptake [VO2] or maximum heart
rate [HR]) [16,17,19-21]. In COPD, programs of 12
weeks duration have been shown to produce greater and
more sustained improvements in exercise outcomes
when compared to programs of shorter duration [20,21].
Historically, exercise training has been discouraged as
a therapy for patients with PAH due to the perceived
risk that exercise could lead to sudden cardiac death or
worsening pulmonary vascular haemodynamics, accel-
eration of vascular remodelling and deterioration in
right heart function [15]. Some evidence exists to sug-
gest that exercise training can be performed without
adverse events or detriment to cardiac function or
pulmonary haemodynamics [10,15,24,25], however, the
efficacy of exercise training in PAH warrants further
investigation [14]. To date, only three prospective stu-
dies of exercise training in PAH populations have been
published [10,15,25]. These studies recruited subjects
with idiopathic PAH or chronic thromboembolic
pulmonary hypertension, who were stable on medical
therapy and were in WHO functional classes II to IV.
The exercise training regimen varied in these studies in
terms of the frequency of sessions each week (ranging
from 3 to 7), duration (7 to 15 weeks) and the exercise
modalities [10,15,25]. The types of exercises performed
included cycle ergometry [10,15,25], walking [15,25],
peripheral muscle training (i.e. quadriceps) [10], breath-
ing exercises [15,25], upper limb exercises [15,25], yoga
[15] and mental conditioning [15]. All three studies
demonstrated significant improvements (p < 0.001) in
exercise tolerance as measured by an increase in 6-
minute walk distance (6MWD) [15,25] or endurance
time on a cycle ergometer [10], one study reporting
improvements in muscle strength and endurance [10].
Improvements in HRQoL (SF-36 component summary
s c o r e s )w e r ea l s or e p o r t e di no n es t u d y( p<0 . 0 5 )[ 1 5 ] .
No adverse events were reported in any of the studies.
The studies to date have demonstrated improvements
in exercise capacity in this patient population [10,15,25],
however these studies have some limitations in the
application of exercise training in Australia. Uchi et al
[25] recruited subjects who had recently commenced
intravenous PAH therapy and thus it is not possible to
differentiate between the benefits of exercise and those
attributed to the medication. The training programs
have included a variety of modalities such as mental
training and yoga [15], interventions that do not form
part of most cardiopulmonary rehabilitation programs.
Within Australia, most rehabilitation programs designed
for cardiac or respiratory populations consist of whole
body exercise training and take place in hospital outpati-
ent departments or in community settings [26,27]. This
contrasts with the study by Mereles et al [15] in which
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program prior to performing a 12 week home exercise
program. In Australia, the resources for providing
inpatient exercise training to individuals who are stable
on medical therapy are limited [24]. The study by de
Man et al [10] evaluated a 12 week outpatient exercise
training program which comprised cycling and quadri-
ceps training. The specificity of lower limb exercise
training in this study is likely to account for the large
increase in endurance cycle time and may explain the
non-significant improvement in 6MWD.
To date, the studies have only reported the immediate
effects of exercise training and thus it remains unknown
whether the benefits are maintained following cessation
of supervised training. It is also unknown whether an
outpatient-based, whole body exercise training program
is beneficial in patients with PAH and whether this type
of program is capable of producing sustained benefits in
exercise capacity and HRQoL.
This study aims to investigate the benefits of a 12
week hospital outpatient-based, individualised exercise
training program involving supervised exercise sessions,
followed by a 12 week home exercise program, for a
cohort of subjects with PAH.
We hypothesise that:
(i) A 12 week individualised, whole body exercise
training program will improve:
￿ Exercise capacity (as assessed by peak VO2;a n a e -
robic threshold; endurance time measured during
the constant-workload cycle ergometry test)
￿ HRQoL
(ii) Exercise training is safe and improvements in exer-
cise capacity will be achieved without evidence of clini-
cal worsening
(iii) An additional 12 week home exercise program
will maintain or further improve the benefits gained
during the 12 week, supervised, outpatient program.
Design/Methods
Design
This study is a prospective, single blind, randomised
controlled trial.
Participants
Thirty-four subjects will be recruited from the Western
Australian State Pulmonary Hypertension Service, at
Royal Perth Hospital, Perth, Western Australia.
Inclusion/Exclusion Criteria
Subjects will be included in the study if they: have a
confirmed diagnosis of idiopathic or familial PAH or
PAH associated with connective tissue disorders, based
on elevated pulmonary artery pressures measured by
right heart catheterisation at rest; are in WHO
functional class II or III (receiving PAH-specific phar-
maceutical therapy); are medically stable and have been
on PAH-specific pharmaceutical therapy for 3 months
prior to enrolment into the study, and, are willing to
complete the supervised and home exercise training
programs. Medical stability will be defined as the
absence of recent changes in: specific PAH therapy (no
change in sildenafil citrate dose for 6 weeks, no change
in endothelial antagonist receptors for 3 months);
inotropes (including digoxin) and diuretics; symptoms
(including dyspnoea and fatigue); body weight and
co-morbid conditions.
Subjects will be excluded if they have: oxygen therapy
requirements; significant musculoskeletal disease, claudi-
cation pain, neurological or cognitive impairment,
psychiatric/psychological or mood disorders that may
affect their ability to undertake exercise testing or train-
ing; a history of moderate or severe chronic lung dis-
ease; cardiac disease associated with cardiac failure,
poorly controlled angina, unstable cardiac rhythm; invol-
vement in a supervised exercise training program within
the last 12 months.
Recruitment and Randomisation
The flow of subjects through the study is based on
recommendations from the Consolidated Standards of
Reporting Trials (CONSORT) statement [28] and out-
lined in Figure 1. Subjects will receive written and verbal
information regarding participation in the study and
written consent will be obtained from all subjects. The
Human Research Ethics Committees of Royal Perth
Hospital and Curtin University have approved this
study. The study protocol has been registered with the
Australian New Zealand Clinical Trials Registry
(ACTRN12609000502235).
All subjects will undergo a baseline assessment and
re-assessment at 12 and 24 weeks. Following baseline
assessment, stratified randomisation to the exercise or
control group will be performed. Permuted block rando-
misation with block sizes of 4 will be used [29]. In order
to achieve groups balanced for exercise capacity,
subjects will be stratified based on the peak VO2 >o r≤
70% of predicted values [30].
Subjects in both groups will receive usual medical
care. Subjects randomised to the exercise group will
undergo a 12 week, individually prescribed, supervised,
outpatient exercise training program, followed by a 12
week home exercise program.
Assessment Procedures
Researchers ‘blinded’ to the subject’s group allocation
will perform all followup assessments. Each subject will
undergo the following procedures at baseline assessment
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to attend 3 assessment visits within a 2 week period,
with each visit separated by at least 24 hours.
Visit 1
Subjects will undergo:
(i) Two unencouraged 6-minute walk tests (separated
by a rest period of at least 30 minutes) that include
monitoring of HR via telemetry (Polar FS3C heart rate
monitor, Sportstek, Victoria, Australia), oxygen satura-
tion (SpO2) (Respironics 512 pulse oximeter and finger
sensor, Philips, Massachusetts, United States) and
assessment of symptoms (Borg CR10 [31] dyspnoea and
rating of perceived exertion [RPE]).
(ii) Familiarisation with the cycle ergometer and gas
analysis equipment.
(iii) HRQoL assessment using the CAMPHOR [32],
which has been recently validated in the Australian
PAH population [33], and the Medical Outcomes Study
Short Form 36 (SF36) Version 2 [34].
(iv) Assessment of physical activity using the Interna-
tional Physical Activity Questionnaire [35].
Visit 2
An incremental cardiopulmonary exercise test (CPET)
using a continuous ramp protocol (Lode Corival cycle
ergometer, Lode, Groningen, Netherlands) [36], to voli-
tional exhaustion with breath by breath gas exchange
analysis (Medical Graphics CPX-D, Medgraphics,
Minnesota, United States) will be carried out. The test
protocol will comprise 3 minutes of upright rest on the
bicycle, followed by 3 minutes of unloaded pedalling
(0 W). Subsequent workloads will be increased by
5W / m i n ,1 0W / m i no r1 5W / m i ni n c r e m e n t sd e p e n d -
ing on the subject’s age, gender, weight, 6MWD and dif-
fusing capacity of the lung for carbon monoxide
(DLCO) [30]. The aim will be to achieve a test duration
of 8 to 12 minutes from commencement of the
incremental phase of the test to peak exercise due to
volitional task cessation or symptom limitation. Stan-
dard criteria will be used to determine if test termina-
tion is required for safety reasons [36].
Visit 3
A constant workload exercise test will be performed
using the same system used for the incremental CPET.
The test protocol will comprise 3 minutes of upright
rest on the bicycle, followed by 3 minutes of unloaded
pedalling (0 W), followed by a step increase in workload
to 75% of the peak workload achieved during the incre-
mental CPET. Subjects will be instructed to cycle until
voluntary task failure, aiming for a test duration of 6 to
8 minutes. The test will be terminated after 20 minutes
of loaded cycling if volitional exhaustion is not reached.
Standard criteria will be used to determine if test termi-
nation is required for safety reasons [36]. Constant
workload cycle tests, at 12 and 24 weeks, will be per-
formed using the identical workload to that used at the
baseline assessment.
Exercise group
Subjects will attend a 12 week, outpatient, individua-
lised, supervised exercise training program involving 3
exercise classes (one hour duration) each week. The
sessions will focus on lower limb endurance training
(walking and cycling). Lower limb functional strength
training (step ups and sit to stands) and endurance
training of the upper limbs will also be included with
the aim of improving the subject’s ability to undertake
activities of daily living. Heart rate will be monitored
continuously via telemetry (Polar FS3C heart rate moni-
tor, Sportstek, Victoria, Australia) and SpO2 (Respiro-
nics 512 pulse oximeter and finger sensor, Philips,
Massachusetts, United States) prior to and following
each exercise. Intensity for the lower limb endurance
exercises will be prescribed with the aim of achieving
60-70% HR max (based on age predicted maximum,
220-age [37]), while maintaining SpO2 ≥ 92% and symp-
tom intensity (Borg CR10 dyspnoea < 4 and RPE < 4).
Exercise intensity will be progressed, based on the indi-
vidual’s response to training to maintain HR within the
target HR range. The lower limb functional strength
training and upper limb endurance exercises will be
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of muscle fatigue (RPE 3 to 4) following the completion
of 2 sets of 10 repetitions.
Home exercise program
The subjects randomised to the exercise group will be
asked to commence one session per week of their home
exercise program during the last 4 weeks of their super-
v i s e dp r o g r a m .T h i si st oe n s u r es u b j e c t sh a v et h e
opportunity to discuss the program with the supervising
physiotherapist who can assist in troubleshooting any
problems that may arise. On completion of the super-
vised program, subjects will increase the frequency of
their home program to 3 sessions per week for an addi-
tional 12 weeks. The home program will comprise lower
limb endurance training (walking) and lower limb func-
tional strength exercises (step ups and sit to stands).
Subjects will be required to record each session on an
exercise log. The program will be individually tailored
based on the individual’s performance during the super-
vised exercise classes. To guide the home exercise train-
ing intensity, symptoms during the supervised period
will be correlated to a HR maximum of 120 bpm [15].
Subjects will aim to achieve these symptom responses
(Borg CR10 dyspnoea < 4 and RPE < 4) at home to
guide exercise intensity.
Withdrawal Criteria
Subjects will be withdrawn from the study if they
demonstrate deterioration in their clinical status (time
to clinical worsening), defined by the presence of two or
more of the following [38,39]: (i) escalation of medical
therapy (increased dose of medication or commence-
ment of intravenous epoprostenol); (ii) deterioration (≥
1) in WHO functional class; (iii) development of right
heart failure (as indicated by increased jugular venous
pressure, new/worsening hepatomegaly, ascites or per-
ipheral oedema); (iv) resting echocardiogram changes
(deterioration in right ventricular size and function,
right atrial size, pulmonary arterial systolic pressure
(PASP) and, where PASP cannot be determined, pul-
monary acceleration time); (v) oedema that does not
respond to oral diuretics; (vi) hospitalisation for PAH;
(vii) listing for transplantation; (viii) ≥ 20% deterioration
in 6MWD (ix) progressive worsening of dyspnoea at
rest or on exertion over the past 3-5 days [40]; (x) dete-
rioration in ventilatory efficiency (VE/VCO2) reflecting
worsening gas exchange.
S u b j e c t sm a ya l s ob ew i t h d r a w nf r o mt h es t u d ya t
their request or if they experience a serious adverse
event during or up to 24 hours following an exercise
training session and it is deemed unsafe to continue
participation by the treating medical officer from the
Royal Perth Hospital Pulmonary Hypertension Service.
Adverse events comprise: (i) an incident requiring a
medical emergency team call (according to Royal Perth
Hospital criteria); (ii) exercise-related incident requiring
presentation to the Emergency Department or General
Practitioner; (iii) hospital admission due to PAH or wor-
sening right heart failure; (iv) an incident resulting in
the patient ceasing exercise during class (chest pain,
syncope, worsening dyspnoea despite rests, hypotension/
hypertension, bradycardia/tachycardia (as measured by a
polar monitor and confirmed by palpation), nausea
(associated with sweating, pallor and/or tremor), vague-
ness, vasovagal, arrhythmia); (v) death.
Outcomes
The primary outcomes of this study will be:
(i) Peak VO2;
(ii) Anaerobic threshold;
(iii) Endurance time measured from the constant
workload cycle ergometry test;
(iv) HRQoL measured using the CAMPHOR and SF
36 Version 2;
(v) The number of reported acute adverse events (i)
reported during exercise training and (ii) resulting in
the withdrawal of a subject from the study.
The secondary outcomes of this study will be:
(i) Ventilatory variables at isotime during the con-
stant workload cycle ergometry test (ventilatory
equivalent for carbon dioxide [VE/VCO2]a n de n d
tidal carbon dioxide [PetCO2] to describe gas
exchange);
(ii) Change in WHO functional class;
(iii) 6MWD (measured from the best of two 6MWTs
at each assessment);
(iv) Worsening clinical status (see withdrawal
criteria).
Sample size calculation
Improvements in endurance time following exercise
training have recently been reported in the PAH popula-
tion [10]. These authors [10] reported a mean increase
in endurance time, as measured from a constant work-
load cycle ergometer test, of 270 seconds. The constant
workload tests were set at 75% of the peak workload
achieved during the incremental CPET, which is consis-
tent with our study’s protocol. The mean endurance
time (standard deviation) at baseline and post-training
were 390 (40) and 660 (60) seconds respectively.
Conservative sample size calculations have been per-
formed using a two-sided Mann-Whitney U test, assum-
ing that the actual distribution is a double exponential.
Group sizes of 14 will achieve 91% power to detect a
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that both group means are 600 seconds and the alterna-
tive hypothesis that the mean of group 2 is 400 seconds
with estimated group standard deviations of 180 and
120 and with a significance level (alpha) of 0.01.
A total of 34 subjects (17 in the exercise group and 17
controls) will be recruited to allow for 20% attrition of
subjects from the per protocol analysis.
Statistical methods
Data will be analysed using SPSS software (Version 17.0;
SPSS Inc; Chi). Data that are not normally distributed
will be transformed and if transformation fails to satisfy
normality, non-parametric tests will be used. The pri-
mary and secondary outcomes in the exercise and con-
trol groups will be compared using two-way analysis of
variance to account for group and time interactions. Sta-
tistical relationships between outcome variables will be
analysed using Pearson’so rS p e a r m a n ’s correlations as
appropriate. Data will be analysed using (i) per protocol
analysis and (ii) intention-to-treat analysis. Per protocol
analysis will be restricted to the data from subjects who
complete all assessments and for the exercise group
who attend at least 75% of their exercise classes. The
required number of sessions must be achieved within a
period of 15 weeks for both the supervised and home
exercise training programs, allowing for intercurrent ill-
ness and other factors that may impact on an indivi-
dual’s ability to attend sessions. The last-observation-
carried-forward method will be used to impute missing
data at 12 and 24 weeks for the intention-to-treat analy-
sis [41]. The Berger-Exner [42] test will be carried out
to determine whether selection bias has been introduced
into the study.
Discussion
This study will be the first randomised controlled trial
to evaluate the physiological, clinical and psychological
changes that occur following outpatient-based, whole
body exercise training in PAH. We hypothesise that
exercise training will improve exercise capacity and
HRQoL. Adverse events and clinical worsening will be
monitored in order to address theoretical safety con-
cerns regarding the potential deleterious effects exercise
may have on the pulmonary vasculature and right heart
function. Assessment of the subjects following 12 weeks
of home exercise program will determine whether the
subjects were able to safely maintain the benefits
achieved during the supervised exercise training period.
Furthermore, this study will contribute to clinical prac-
tice guidelines, which will have important implications
for the future management of patients with PAH.
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